← Back to all signals
RESEARCH PAPER ANALYSIS

Biomechanical adaptation to repeated slips during standing in people with Parkinson's disease.

This small feasibility study shows people with Parkinson's disease can safely tolerate repeated high‑intensity treadmill-induced standing-slips and rapidly improve dynamic gait stability, limb support, and recovery-step metrics across trials.

PMID42048693
JournalJournal of biomechanics
Publication Date2026-04-18
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This small feasibility study shows people with Parkinson's disease can safely tolerate repeated high‑intensity treadmill-induced standing-slips and rapidly improve dynamic gait stability, limb support, and recovery-step metrics across trials.

WHY IT MATTERS

Research significance

While not addressing molecular or drug targets, the paper provides actionable translational evidence that perturbation-based balance training is feasible and adaptive in PD and therefore a promising non-pharmacologic intervention to test in clinical trials to reduce fall risk.

ABSTRACT

Source abstract

Falls are a major concern in people with Parkinson's disease (PwPD). Although perturbation-based balance training could reduce fall risk, it remains unclear whether PwPD can tolerate and adapt to repeated large-scale stance perturbations. This study examined the feasibility of applying large-scale standing-slips to PwPD and their capacity for rapid adaptation to recurrent slips. Ten PwPD experienced five unexpected standing-slips induced by a standardized-magnitude acceleration-deceleration treadmill perturbation on an ActiveStep treadmill, while wearing a safety harness. Dynamic gait stability and limb support were calculated at slip onset (ON) and at recovery step liftoff (LO) and touchdown (TD), serving as the primary outcome measures. Secondary outcomes included recovery-step latency, duration, length, speed, slip distance, and faller rate. Adaptive changes across trials were assessed using repeated-measures ANOVA or Friedman tests, followed by paired t-tests or Wilcoxon tests, respectively. No participants reported injuries or discomfort related to the slips. They demonstrated significant improvements in dynamic gait stability at ON, LO, and TD (p = 0.005 - 0.017) and limb support (p = 0.010 at LO and 0.020 at TD) across repeated slips. Recovery step latency was shorter in later trials (p = 0.013), accompanied by a reduction in slip distance at LO (p = 0.018). The faller rate declined from 70% on the first slip to 40% on the last (p = 0.187). PwPD tolerated high-intensity standing-slips and rapidly adapted to repeated slips by refining dynamic gait stability, limb support, and recovery step performance during slips. The findings can inform future trials of applying standing-slips to PwPD to reduce their fall risk.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic